Disease modifying therapies in heart failure: an update.

IF 7.3 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

QJM: An International Journal of Medicine Pub Date : 2025-03-01 DOI:10.1093/qjmed/hcaf060

Atsushi Tanaka, Koichi Node

引用次数: 0

Abstract

There is currently limited evidence-based disease-modifying pharmacotherapy in patients with heart failure and mildly reduced/preserved ejection fraction (HFmrEF/HFpEF), forming an unmet clinical need in contemporary heart failure care. However, according to the finding from recent clinical trials with some medications such as finerenone and glucagon-like peptide-1 receptor agonist, a clinical concept of pharmacological therapy in patients with HFmrEF/HFpEF will be updated and upgraded. Based on recent evidences, we herein aim to discuss the possible roles of those medications in the HFmrEF/HFpEF therapy and propose an emerging pharmacological strategy for this population.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

QJM: An International Journal of Medicine 医学-医学：内科

CiteScore

6.90

自引率

5.30%

发文量

263

审稿时长

4-8 weeks

期刊介绍： QJM, a renowned and reputable general medical journal, has been a prominent source of knowledge in the field of internal medicine. With a steadfast commitment to advancing medical science and practice, it features a selection of rigorously reviewed articles. Released on a monthly basis, QJM encompasses a wide range of article types. These include original papers that contribute innovative research, editorials that offer expert opinions, and reviews that provide comprehensive analyses of specific topics. The journal also presents commentary papers aimed at initiating discussions on controversial subjects and allocates a dedicated section for reader correspondence. In summary, QJM's reputable standing stems from its enduring presence in the medical community, consistent publication schedule, and diverse range of content designed to inform and engage readers.